Spero Therapeutics (SPRO) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $48.6 million.
- Spero Therapeutics' Cash & Equivalents fell 3627.47% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 3627.47%. This contributed to the annual value of $52.9 million for FY2024, which is 3071.28% down from last year.
- Spero Therapeutics' Cash & Equivalents amounted to $48.6 million in Q3 2025, which was down 3627.47% from $31.2 million recorded in Q2 2025.
- Over the past 5 years, Spero Therapeutics' Cash & Equivalents peaked at $112.9 million during Q3 2021, and registered a low of $31.2 million during Q2 2025.
- In the last 5 years, Spero Therapeutics' Cash & Equivalents had a median value of $76.3 million in 2024 and averaged $73.6 million.
- In the last 5 years, Spero Therapeutics' Cash & Equivalents crashed by 5530.17% in 2022 and then skyrocketed by 8599.1% in 2023.
- Quarter analysis of 5 years shows Spero Therapeutics' Cash & Equivalents stood at $112.6 million in 2021, then dropped by 3.09% to $109.1 million in 2022, then tumbled by 30.04% to $76.3 million in 2023, then plummeted by 30.71% to $52.9 million in 2024, then fell by 8.08% to $48.6 million in 2025.
- Its Cash & Equivalents was $48.6 million in Q3 2025, compared to $31.2 million in Q2 2025 and $48.9 million in Q1 2025.